Vol 61, No 1 (2010)
Original paper
Published online: 2010-03-04

open access

Page views 736
Article views/downloads 1656
Get Citation

Connect on Social Media

Connect on Social Media

The prevalence of benign and malignant neoplasms in acromegalic patients

Agata Bałdys-Waligórska, Anna Krzentowska, Filip Gołkowski, Grzegorz Sokołowski, Alicja Hubalewska-Dydejczyk
Endokrynol Pol 2010;61(1):29-34.


Introduction: In acromegalic patients, the prevalence of certain benign and malignant neoplasms is higher than that in the healthy population. We retrospectively evaluated the prevalence of tumours in acromegalic patients treated at our department: the regional centre for acromegalic patients for the Małopolskie voivodeship in Poland.
Material and methods: During the years 1983-2008, a hundred and one acromegalic patients (30 males and 71 women), of mean age 51.8 ± 15.4 years, were diagnosed and treated. Pituitary macroadenoma and microadenoma were stated in 63.4% and 25.7% of these patients, respectively. In 10.9% of these patients no data on tumour diameter were available. The mean observation period was 9.4 ± 6.5 years. The median levels of hGH and IGF-1 prior to neurosurgery were 20.2 (IQR = 34.9) ng/ml and 764.5 (IQR = 569.6) ng/ml, respectively.
Results: In the studied group of patients, we found the following prevalence of various tumours: nodular goitre - 64/101 patients (63.0%), polyps of the colon - 13/101 patients (13.0%); uterine polyps - 4/101 patients (4.0%); and prostate adenoma - 2/101 patients (2.0%). Among malignant tumours, thyroid cancer, endometrium and cervix cancer were the most frequent, each of these occurring in 3 patients (3.0%). Colon cancer prevalence was 2.0% (in 2 patients).
Conclusions: From our retrospective study, we suggest an overall increase of tumour incidence in acromegalic patients. Prospective multicentre studies are required to resolve the significance of this observation. In our study group, the number of malignant neoplasms was significantly higher in patients with long-lasting uncontrolled disease (over 5 years), compared to patients with controlled disease.
(Pol J Endocrinol 2010; 61 (1): 29-34)

Article available in PDF format

View PDF Download PDF file